TG Therapeutics (NASDAQ:TGTX) Shares Up 4.2%

TG Therapeutics, Inc. (NASDAQ:TGTX) shares shot up 4.2% on Monday . The company traded as high as $20.97 and last traded at $20.75. 411,876 shares traded hands during mid-day trading, a decline of 89% from the average session volume of 3,651,545 shares. The stock had previously closed at $19.92.

Analyst Ratings Changes

TGTX has been the topic of a number of analyst reports. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a report on Thursday, April 18th. The Goldman Sachs Group increased their target price on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a report on Tuesday, August 6th. LADENBURG THALM/SH SH increased their target price on TG Therapeutics from $39.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, May 2nd. Finally, B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Trading Up 0.5 %

The company has a market cap of $3.30 billion, a PE ratio of 92.30 and a beta of 2.23. The business has a 50 day simple moving average of $18.93 and a two-hundred day simple moving average of $16.73. The company has a current ratio of 3.62, a quick ratio of 2.84 and a debt-to-equity ratio of 0.63.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a return on equity of 31.34% and a net margin of 14.24%. The company had revenue of $73.47 million for the quarter, compared to analyst estimates of $65.92 million. During the same quarter in the prior year, the company posted ($0.34) EPS. The business’s revenue for the quarter was up 357.0% compared to the same quarter last year. On average, analysts forecast that TG Therapeutics, Inc. will post -0.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TGTX. Hood River Capital Management LLC purchased a new position in shares of TG Therapeutics in the 1st quarter worth $22,420,000. Norges Bank purchased a new position in shares of TG Therapeutics in the 4th quarter valued at $18,362,000. Assenagon Asset Management S.A. acquired a new position in shares of TG Therapeutics during the 2nd quarter valued at $8,698,000. Eventide Asset Management LLC acquired a new position in shares of TG Therapeutics during the 4th quarter valued at $7,506,000. Finally, Opaleye Management Inc. boosted its position in TG Therapeutics by 17.2% during the 4th quarter. Opaleye Management Inc. now owns 2,215,000 shares of the biopharmaceutical company’s stock worth $37,832,000 after purchasing an additional 325,000 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.